Niagen Bioscience Q1 Earnings

Niagen Bioscience (NASDAQ: NAGE) reaffirmed its full-year revenue growth target on Wednesday, Benzinga reported, following a first quarter that delivered higher profits and steady top-line expansion. Despite the upbeat results, NAGE shares dropped more than 7% in after-hours trade.

Forecast Held as Spending Rises

The Niagen Bioscience sales forecast remains a 10%-15% increase in full-year net sales. That projection excludes revenue from a unit the company has already divested. Management pointed to e-commerce momentum and fresh commercial partnerships as the primary growth engines. The company also trimmed its general and administrative expense outlook, now guiding for a $3M-$4M increase versus a prior range of $4M-$5M. Sales and marketing outlays, however, are expected to climb as the company pursues new customer segments and product verticals.

First-Quarter Results Show Income Expansion

First-quarter net sales reached $31.5M, up 3% from the same period a year ago. On an adjusted basis stripping out the divested segment, the gain was 5%. Net income advanced to $6.3M from $5.1M in the prior-year quarter. Operating expenses rose a sharper 26% to $18.4M, reflecting heavier investment in advertising, research, and commercial buildout. The widening gap between revenue growth and expense growth is one factor investors appear to be weighing in after-hours activity.

Background: NAD Supplements and a Crowded Market

Founded in 1999, the Los Angeles-based company produces supplements containing nicotinamide riboside, a precursor compound the body converts into NAD+. NAD+ is a coenzyme critical to cellular energy metabolism but naturally declines with age. The active ingredient has passed FDA safety reviews, though Tru Niagen is not approved to treat or prevent any disease. The product gained wider consumer recognition partly through its association with longevity entrepreneur Bryan Johnson, who publicly incorporates it into his wellness regimen. The segment has grown increasingly competitive as interest in longevity science accelerates.

New Verticals Fuel Next Growth Phase

Beyond its core supplement line, Niagen has been building out adjacent categories. The company recently introduced a clinician-directed telehealth service offering prescription at-home injection kits. It also entered skincare through a topical product range called Nanocloud. Those moves signal an effort to deepen its footprint across the broader wellness and longevity market. Year-to-date, NAGE shares remain down roughly 20%, reflecting persistent pressure even as short-term price momentum has recently turned positive.

Read Next: What the Longevity Economy Means for Biotech Investors